The most important biotech funding rounds in February 2025

The businesses Eikon Therapeutics, Sionna Therapeutics, and Abcuro bagged the largest biotech funding rounds total in February 2025 throughout non-public and public funding sorts. On this article, we break down final month’s non-public and public fundraising exercise, trying on the largest rounds in additional element.

Personal biotech funding rounds in February 2025

First, let’s check out the non-public biotech investments in February 2025, breaking them down by worth, location, funding sort, and therapeutic subsector.

Greatest non-public biotech funding rounds by worth

In February 2025, Eikon Therapeutics raised the most important non-public biotech funding, bringing in a really spectacular $350.7 million in sequence D funding. The proceeds will assist it to additional advance its lead drug candidate, EIK1001, which is a systemically administered co-agonist of toll-like receptors 7 and eight at the moment being examined in a part 3 trial for superior melanoma.

The second largest spherical final month went to Abcuro, because it raised $200 million in sequence C financing to assist it full a part 2/3 trial of ulviprubart, a first-in-class monoclonal antibody concentrating on killer cell lectin like receptor G1 (KLRG1), for the remedy of inclusion physique myositis (IBM). In the meantime, AdvanCell got here third within the rankings after elevating $112 million in an oversubscribed sequence C spherical, which is able to permit the corporate to advance ongoing efforts to broaden its manufacturing capability and speed up the medical improvement of its pipeline of radionuclide therapies.

Personal biotech funding rounds by location

February 2025 unusually noticed Europe have extra funding rounds than North America, with six in whole in comparison with North America’s 4. Nonetheless, it was nonetheless North America that introduced within the largest amount of cash, as firms within the area raised a complete of $734.2 million, which equated to 78.2% of the whole cash raised by all areas all through the month. Even Asia-Pacific managed to boost more cash in whole than Europe, because of Australian firm AdvanCell’s $112 million spherical.

Personal biotech funding rounds by funding sort

Final month, there have been as soon as once more extra sequence A rounds than every other sort, with three in whole. However the largest amount of cash was truly introduced in from sequence D funding, regardless of there solely being one spherical of this sort; this was because of Eikon Therapeutics’ $350.7 million financing.

Personal biotech funding rounds by therapeutic subsector

When taking a look at funding rounds by therapeutic subsector in February 2025, we will see that oncology firms as soon as once more attracted essentially the most rounds (3) and introduced within the largest amount of cash, elevating $470.9 million in whole. And, because of Abcuro’s $200 million financing spherical, the autoimmune illnesses subsector introduced within the second-largest quantity of funding final month, regardless of there solely being one spherical.

Public biotech funding rounds in February 2025

Now, let’s try the general public biotech fundraising rounds that occurred in February 2025, breaking them down by worth and therapeutic subsector.

Public biotech funding by worth

In February 2025, Sionna Therapeutics bagged the most important public fundraising of the month, bringing in $219.2 million by an preliminary public providing (IPO). This may assist to fund the corporate’s mission of revolutionizing the present remedy paradigm for cystic fibrosis by creating novel medicines that normalize the operate of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

In the meantime, Tectonic Therapeutic raised the second-largest quantity after it introduced in $185 million from a personal funding in public fairness (PIPE), and Oculis raised the third-largest quantity after attracting $100 million from a public providing.

Public biotech funding by therapeutic subsector

The endocrinology and metabolic issues therapeutic subsector attracted essentially the most rounds (2) final month, in addition to the most important amount of cash, as firms centered on this space introduced in $279.2 million in whole. Plus, it’s value noting that, in full distinction to non-public fundraising final month, the sphere of oncology attracted the least amount of cash when it got here to public biotech investments.

Month-to-month comparability of biotech fundraising

Beneath is a graph exhibiting a month-to-month comparability of personal and public biotech fundraising, trying on the whole amount of cash raised monthly in 2025. 

From the graph, we will see that February was a poor month for each non-public and public fundraising in comparison with January. Particularly, there was an infinite distinction in non-public funding, with round $3 billion amassed in January versus simply $939 million in February.